Investors

Xcede Technologies' Announces Favorable Results from ISO 10993-1 Biological Evaluation of Medical Devices - Part 1 Studies

SEATTLE, Oct. 3, 2017 /PRNewswire/ -- Xcede Technologies announced today that they have completed the bulk of the required ISO 10993-1 Testing Program for the Xcede Hemostatic Patch.  These studies are based on the international standard for medical devices that come into direct or indirect contact with the human body in order to determine the potential for an unacceptable adverse biological response.  They include, but are not limited to, nonclinical (in vitro and non-human) acute and long-term toxicity studies as well as tests of mutagenesis, hemo- and cyto-compatibility, sensitization, and irritation.  Although the chronic liver implantation study is still ongoing, we believe the results to date from the cohort of studies demonstrate a profile appropriate to initiate the filing for regulatory approval to begin clinical trials.  Subject to such regulatory approvals, the Company anticipates starting clinical trials in the Netherlands in early 2018.

"We are very excited to announce these preclinical results," said Linda Zuckerman, Ph.D., President and CEO of Xcede Technologies., Inc.   "We feel this is a significant accomplishment in moving the Xcede Patch to the clinical development phase of the product's life-cycle."

Xcede is committed to the development and manufacturing of innovative hemostatic and sealant products for surgical application including severe, traumatic bleeding.  

Xcede Technologies, a subsidiary of Dynasil Corporation of America is based in Seattle, WA and began operations in October 2013 following a technology transfer from DBM.     

Safe Harbor 
This news release may contain forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements regarding future events and our future results are based on current expectations, estimates, forecasts, and projections and the beliefs and assumptions of our management, including, without limitation, our expectations regarding results of operations, the commercialization of our technology, in particular the Xcede patch, the success of efforts to fund Xcede, positive outcomes of our pre-clinical and planned clinical trials, regulatory approvals and the strength of our intellectual property portfolio.  These forward-looking statements may be identified by the use of words such as "plans", "intends," "may," "could," "expect," "estimates," "anticipates," "continue" or similar terms, though not all forward-looking statements contain such words.  The actual results of the future events described in such forward looking statements could differ materially from those stated in such forward looking statements due to a number of important factors. These factors that could cause actual results to differ from those anticipated or predicted include, without limitation, our ability to develop and commercialize the Xcede patch, including obtaining regulatory approvals, the size and growth of the potential markets for our products and our ability to serve those markets, the rate and degree of market acceptance of any of our products, general economic conditions, costs and availability of raw materials and management information systems, our ability to obtain and maintain intellectual property protection for our products, competition, the loss of key management and technical personnel, our ability to obtain timely payment of our invoices to governmental customers, litigation, the effect of governmental regulatory developments, the availability of financing sources, our ability to identify and execute on acquisition opportunities and integrate such acquisitions into our business, and seasonality, as well as the uncertainties set forth in Dynasil Corporation of America's Annual Report on Form 10 K, as filed on December 21, 2016 and from time to time in the Company's other filings with the Securities and Exchange Commission. Dynasil Corporation of America disclaims any intention or obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Dynasil Corporation of America disclaims any intention or obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:
Patty Kehe (Dynasil Corp of America)
Xcede Technologies, Inc.
P.O Box 75328
Seattle, WA 98175
Phone: (617) 668-6855
pkehe@dynasil.com

SOURCE Xcede Technologies, Inc.


print email rss
Optometrics

Learn How a Diffraction Grating is Used for an Optical Sight

Memberships & Certifications

Back Save & Share Cart
Your Shopping Cart will be saved with Product pictures and information, and Cart Totals. Then send it to yourself, or a friend, with a link to retrieve it at any time.
Your cart email sent successfully :)

Save & Share Cart
Your Shopping Cart will be saved and you'll be given a link. You, or anyone with the link, can use it to retrieve your Cart at any time.